(600211)"Tibet Rhodiola Pharmaceutical Holding Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 600211 · · 18 pages · Chinese
Summary by 6ix AI
The report confirms the accuracy and completeness of the financial information presented, with the board of directors assuming legal responsibility for its content. The report also highlights the establishment of a joint venture aimed at expanding the company's market presence and product offerings.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Tibet Rhodiola Pharmaceutical Holding Co. on 6ix
Earlier from Tibet Rhodiola Pharmaceutical
- (600211)"Tibet Rhodiola Pharmaceutical Holding Co., Ltd."Announcement on Obtaining U.S. FDA Clinical Trial Approval for ART002g1 Injection by Controlled Subsidiary
- (600211)"Tibet Rhodiola Pharmaceutical Holding Co., Ltd."Announcement on Release of Pledge of Certain Shares Held by Shareholder Holding More Than 5% of the Shares
- (600211)"Tibet Rhodiola Pharmaceutical Holding Co., Ltd."Announcement on Progress in Repurchasing Shares
- Announcement on Implementation of Dividend Distribution for the First Half of 2026
- Announcement on Outline of the 2026 Semi-annual Performance Briefing
Later from Tibet Rhodiola Pharmaceutical
All Tibet Rhodiola Pharmaceutical news releasesFollow Tibet Rhodiola Pharmaceutical into a list and get an email when it puts out news.
Follow Tibet Rhodiola Pharmaceutical